. "3" . "6"^^ . "15310" . . . . "RIV/61989592:15310/09:00010067" . "\u0160tarha, Pavel" . "Popa, Igor" . . . . "Van\u010Do, J\u00E1n" . "Dinuclear copper(II) complexes containing 6-(benzylamino)purines as bridging ligands: Synthesis, characterization, and in vitro and in vivo antioxidant activities" . . "Dinuclear copper(II) complexes containing 6-(benzylamino)purines as bridging ligands: Synthesis, characterization, and in vitro and in vivo antioxidant activities"@en . "9"^^ . "RIV/61989592:15310/09:00010067!RIV10-MSM-15310___" . . . . "Tr\u00E1vn\u00ED\u010Dek, Zden\u011Bk" . "A series of dinuclear copper(II) complexes involving 6-(benzylamino)purine derivatives, (HLn), as bridging ligands were synthesized, characterized and tested for both their in vitro and in vivo antioxidant activities. Based on results of elemental analyses, temperature dependence of magnetic susceptibility measurements, UV-VIS, FTIR, EPR, NMR and MALDI-TOF mass spectroscopy, conductivity measurements and thermal analyses, the complexes with general compositions of [Cu2(\u03BC-HLn)4Cl2]Cl2?2H2O (1?4) and [Cu2(\u03BC-HLn)2(\u03BC-Cl)2Cl2] (5?7) were prepared {where n = 1?4; HL1 = 6-[(2-methoxybenzyl)amino]purine, HL2 = 6-[(4-methoxybenzyl)amino]purine, HL3 = 6-[(2,3-dimethoxybenzyl)amino]purine and HL4 = 6-[(3,4-dimethoxybenzyl)amino]purine}. In the case of complexes 2, 3, 5 and 7, the antioxidant activities were studied by both in vitro {superoxide dismutase-mimic (SOD-mimic) activity} and in vivo {cytoprotective effect against the alloxan-induced diabetes (antidiabetic activity)} methods. The obtained" . "Dinuclear copper(II) complexes containing 6-(benzylamino)purines as bridging ligands: Synthesis, characterization, and in vitro and in vivo antioxidant activities" . "103" . . . "Such\u00FD, Pavel" . "Dinuclear copper(II) complexes containing 6-(benzylamino)purines as bridging ligands: Synthesis, characterization, and in vitro and in vivo antioxidant activities"@en . . "A series of dinuclear copper(II) complexes involving 6-(benzylamino)purine derivatives, (HLn), as bridging ligands were synthesized, characterized and tested for both their in vitro and in vivo antioxidant activities. Based on results of elemental analyses, temperature dependence of magnetic susceptibility measurements, UV-VIS, FTIR, EPR, NMR and MALDI-TOF mass spectroscopy, conductivity measurements and thermal analyses, the complexes with general compositions of [Cu2(\u03BC-HLn)4Cl2]Cl2?2H2O (1?4) and [Cu2(\u03BC-HLn)2(\u03BC-Cl)2Cl2] (5?7) were prepared {where n = 1?4; HL1 = 6-[(2-methoxybenzyl)amino]purine, HL2 = 6-[(4-methoxybenzyl)amino]purine, HL3 = 6-[(2,3-dimethoxybenzyl)amino]purine and HL4 = 6-[(3,4-dimethoxybenzyl)amino]purine}. In the case of complexes 2, 3, 5 and 7, the antioxidant activities were studied by both in vitro {superoxide dismutase-mimic (SOD-mimic) activity} and in vivo {cytoprotective effect against the alloxan-induced diabetes (antidiabetic activity)} methods. The obtained"@en . . "Z(MSM6198959218)" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . . . "Herchel, Radovan" . . "310622" . "0162-0134" . "Journal of Inorganic Biochemistry" . . . "Copper(II); 6-(benzylamino)purine; SOD-mimic activity; antidiabetic activity; dinuclear complexes"@en . "5"^^ . "[EF7FC9386421]" .